An open-label, long-term safety study to evaluate the safety of the ZR-02-01 matrix transdermal fentanyl patch for the treatment of moderate to severe cancer pain

Trial Profile

An open-label, long-term safety study to evaluate the safety of the ZR-02-01 matrix transdermal fentanyl patch for the treatment of moderate to severe cancer pain

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual patient number is 24 and additional lead trial investigator (Richard Rauck) identified as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top